Dolan Sondhi

List of Publications by Year
in descending order

37	1,838	331670 21	330143 37
papers	citations	h-index	g-index

37	37	37	1984
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. Human Gene Therapy, 2021, 32, 563-580.	2.7	18
2	Automated Retinal Layer Segmentation in CLN2-Associated Disease: Commercially Available Software Characterizing a Progressive Maculopathy. Translational Vision Science and Technology, 2021, 10, 23.	2.2	2
3	Longâ€term functional correction of cystathionine Î²â€synthase deficiency in mice by adenoâ€associated viral gene therapy. Journal of Inherited Metabolic Disease, 2021, 44, 1382-1392.	3.6	7
4	Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy. Human Gene Therapy, 2020, 31, 57-69.	2.7	13
5	Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich's Ataxia Corrected by AAV-mediated Gene Therapy. Human Gene Therapy, 2020, 31, 819-827.	2.7	23
6	Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Science Translational Medicine, 2020, 12, .	12.4	35
7	Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease. Ophthalmology Retina, 2020, 4, 728-736.	2.4	14
8	Cocaine vaccine dAd5GNE protects against moderate daily and high-dose â€œbingeâ€•cocaine use. PLoS ONE, 2020, 15, e0239780.	2.5	18
9	Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1081-1089.	5.7	31
10	Advances in the treatment of neuronal ceroid lipofuscinosis. Expert Opinion on Orphan Drugs, 2019, 7, 473-500.	0.8	20
11	Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2. Experimental Neurology, 2018, 306, 22-33.	4.1	16
12	AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Human Gene Therapy Clinical Development, 2018, 29, 24-47.	3.1	90
13	Biology of the Adrenal Gland Cortex Obviates Effective Use of Adeno-Associated Virus Vectors to Treat Hereditary Adrenal Disorders. Human Gene Therapy, 2018, 29, 403-412.	2.7	29
14	In Vivo Potency Assay for Adeno-Associated Virusâ€“Based Gene Therapy Vectors Using AAVrh.10 as an Example. Human Gene Therapy Methods, 2018, 29, 146-155.	2.1	18
15	Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease). Scientific Reports, 2018, 8, 15229.	3.3	21
16	Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. The Lancet Child and Adolescent Health, 2018, 2, 582-590.	5.6	84
17	Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 244-257.	0.7	14
18	Genetic Modification of the Lung Directed Toward Treatment of Human Disease. Human Gene Therapy, 2017, 28, 3-84.	2.7	37

#	Article	IF	Citations
19	Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. Journal of Allergy and Clinical Immunology, 2016, 138, 1652-1662.e7.	2.9	33
20	Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. Journal of Neuroscience, 2016, 36, 12425-12435.	3.6	53
21	Brain Regionâ€"Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease). American Journal of Neuroradiology, 2016, 37, 1160-1169.	2.4	19
22	Gene therapy for metachromatic leukodystrophy. Journal of Neuroscience Research, 2016, 94, 1169-1179.	2.9	64
23	Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of Aging, 2016, 44, 159-172.	3.1	59
24	Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. PLoS ONE, 2016, 11, e0162978.	2.5	19
25	Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. Human Gene Therapy Clinical Development, 2015, 26, 113-124.	3.1	68
26	Partial Correction of the CNS Lysosomal Storage Defect in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis by Neonatal CNS Administration of an Adeno-Associated Virus Serotype rh.10 Vector Expressing the Human CLN3 Gene. Human Gene Therapy, 2014, 25, 223-239.	2.7	37
27	Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption. Journal of Controlled Release, 2014, 196, 71-78.	9.9	70
28	Cannulation of the internal carotid artery in mice: A novel technique for intra-arterial delivery of therapeutics. Journal of Neuroscience Methods, 2014, 222, 106-110.	2.5	11
29	Advances in the treatment of neuronal ceroid lipofuscinosis. Expert Opinion on Orphan Drugs, 2013, 1, 951-975.	0.8	6
30	Spectrum of Ocular Manifestations inÂCLN2-Associated Batten (Jansky-Bielschowsky)ÂDisease Correlate with Advancing Age and Deteriorating Neurological Function. PLoS ONE, 2013, 8, e73128.	2.5	36
31	Long-Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Nonhuman Primates for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis. Human Gene Therapy Methods, 2012, 23, 324-335.	2.1	84
32	Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. Journal of Neurosurgery: Pediatrics, 2010, 6, 115-122.	1.3	60
33	Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Experimental Neurology, 2008, 213, 18-27.	4.1	59
34	Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNA. Human Gene Therapy, 2008, 19, 463-474.	2.7	366
35	Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Adeno-associated Virus Vector. Molecular Therapy, 2007, 15, 481-491.	8.2	153
36	Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the HumanCLN2cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis. Human Gene Therapy, 2004, 15, 1131-1154.	2.7	118

#	Article	IF	Citations
37	Feasibility of Gene Therapy for Late Neuronal Ceroid Lipofuscinosis. Archives of Neurology, 2001, 58, 1793.	4.5	33